Needham Maintains Buy on Biogen, Raises Price Target to $290
Benzinga Newsdesk 4 days ago
Analyst RatingsNewsPrice Target
Needham analyst Ami Fadia maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $256 to $290.
Needham analyst Ami Fadia maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $256 to $290.